NCT04975997: Phase 3: IberDd Versus DVd in Participants With Relapsed Refractory Myeloma - EXCALIBER
Updated: Aug 25, 2022
Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Participants With Relapsed or Refractory Multiple Myeloma (RRMM) (EXCALIBER-RRMM)
CC-220-MM-002
This is a multicenter, randomized, controlled, open-label, Phase 3 study comparing the efficacy and safety of iberdomide in combination with dexamethasone and daratumumab (IberDd) versus daratumumab, bortezomib, and dexamethasone (DVd) in participants with relapsed or refractory multiple myeloma (RRMM).
Sponsor
Celgene
Multiple Locations
International Study
ClinicalTrials.gov Identifier: NCT04975997
Official Title: A Phase 3, Randomized, Multicenter, Open-label Study Comparing Iberdomide, Daratumumab and Dexamethasone (IberDd) Versus Daratumumab, Bortezomib, and Dexamethasone (DVd) in Subjects With Relapsed or Refractory Multiple Myeloma (RRMM)
First Posted : July 26, 2021
Click here to see details on ClinicalTrials.gov
Drug: CC-220
Drug: Dexamethasone
Drug: Daratumumab
Drug: Bortezomib
Locations
United States, Florida
United States, Georgia
United States, Louisiana
United States, Maryland
United States, Massachusetts
United States, Missouri
United States, New Jersey
United States, New York
United States, Ohio
United States, Pennsylvania
United States, Tennessee
United States, Texas
United States, Wisconsin
Canada
Canada, Alberta
Canada, British Columbia
Canada, New Brunswick
Canada, Newfoundland and Labrador
Canada, Nova Scotia
Canada, Ontario
Canada, Quebec
Canada, Saskatchewan
China
Europe
United Kingdom
France
Germany
Italy
Netherlands
Sweden
Austria
Belgium
Czechia
Denmark
Finland
Greece
Ireland
Norway
Poland
Portugal
Sweden
Switzerland
Turkey
Asia
Japan
Israel
Korea, Republic of
Russian Federation
Taiwan
Australia
Australia, Queensland
Australia, South Australia
Australia, Victoria
Australia, Western Australia